View the event
| Reference: | 4879 |
| Country: | China |
| Multiple country event: | No |
| Region: | WPRO |
| City: | Kaifeng, Lianyungang |
| Start date: | 8 April 2012 |
| End date: | 14 April 2012 |
| Estimated duration: | |
| Status: | Completed - Complété |
| | (The mission has taken place) |
|
| Title: | Provide TA for control multidrug-resistant tuberculosis |
| Type: | Mission |
| Terms of Reference: | Objectives/purpose of travel: WHO headquarters and the Country Office (People's Republic of China) are providing technical assistance to local investigators in the context of a China Ministry of Health/Bill and Melinda Gates Foundation collaborative project to control multidrug-resistant tuberculosis. Study protocols have been developed with WHO support for a cost and cost-effectiveness analysis of the model of management and financing being piloted in four provinces. Data is currently being collected by local investigators on health system and patient costs for the cohort of patients enrolled during 2011. Final outcomes will not be known for another 2 years. In the meantime, WHO is to provide guidance to the local investigators in the economic evaluation based on available 6-month smear and culture conversion outcomes. This will inform government policy on scale-up in the second phase of the project. WHO has been requested to develop the methods for this evaluation in accordance with international standards for cost-effectiveness analysis of MDR-TB management, as has already been applied in four other countries. The objectives of the fields visits to two of the pilot project sites, Kaifeng and Lianyungang, included: 1. To summarize the major constraints to MDR-TB scale-up in China, with particular focus on the economic incentives of and interactions between hospitals and China CDC, and reimbursement under existing insurance schemes, as a follow up to Director STB’s visit to Lianyungang two weeks earlier. 2. To clarify issue of the low rate of project enrolment in some of the sites, especially for poor and complicated cases; relatedly, to ascertain what information is being collected on un-enrolled cases of MDR-TB, and whether these could be used as comparator group in the absence of good baseline outcome data. 3. To review data collection forms to make sure complete and clear for the purposes of the cost and cost-effectiveness analysis, then oversee data collection in patient and other interviews, review preliminary data, identify any early problems, and suggest corrective actions for the local investigators.
|
| Training Opportunity: | No |
| Website: | |
| Purpose 1: | M&E/supervision/ impact measurement |
| Purpose 2: | MDR-TB / XDR-TB |
| Purpose 3: | |
| Other purpose: | |
|
| Entered by: | WHO/HQ |
| Partner 1: | |
| Partner 2: | |
| Partner 3: | |
| Contact name: | TBTEAM |
| Contact email: | tbteam@who.int |
| Other agencies: | |
|
| Funding needs: | No |
| Funding source: | |
| Other funding source: | |
| Available funding: | $ 0 |
| Funding gap: | $ 0 |
| Global Fund reference: | |
|
| Comments: | |
| |
There are no documents attached associated with this event. There are no experts (roster) associated with this event.
Date Created: 12 February 2013
Entered By: TBTEAM Admin
|
